- $1.48bn
- $890.61m
- 47
- 26
- 40
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.57 | ||
| Price to Tang. Book | 2.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.52% | ||
| Return on Equity | -44.83% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 61.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
Directors
- Kurt Von Emster NEC (53)
- Marshall Fordyce CEO (47)
- Sean Grant CFO (37)
- Tom Doan SVP
- Joanne Curley EXO (53)
- Lauren Frenz EXO
- Celia Lin OTH (46)
- Kimball Hall DRC
- Andrew Cheng IND (54)
- Patrick Enright IND (59)
- Maha Katabi IND (47)
- Scott Morrison IND (63)
- Beth Seidenberg IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 17th, 2016
- Public Since
- May 14th, 2021
- No. of Shareholders
- 17
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 63,771,720
- Address
- 2000 Sierra Point Parkway, Suite 1200, BRISBANE, 94005
- Web
- https://veratx.com/
- Phone
- +1 6507700077
- Auditors
- KPMG LLP
Upcoming Events for VERA
Vera Therapeutics Inc Annual Shareholders Meeting
Vera Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Vera Therapeutics Inc Earnings Release
Similar to VERA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Vera Therapeutics share price?
As of Today at 23:57 UTC, shares in Vera Therapeutics are trading at $23.22. This share price information is delayed by 15 minutes.
How has the Vera Therapeutics share price performed this year?
Shares in Vera Therapeutics last closed at $23.22 and the price had moved by -39.98% over the past 365 days. In terms of relative price strength the Vera Therapeutics share price has underperformed the S&P500 Index by -44.6% over the past year.
What are the analyst and broker recommendations for Vera Therapeutics?
The overall consensus recommendation for Vera Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vera Therapeutics dividend yield?
Vera Therapeutics does not currently pay a dividend.
Does Vera Therapeutics pay a dividend?
Vera Therapeutics does not currently pay a dividend.
When does Vera Therapeutics next pay dividends?
Vera Therapeutics does not currently pay a dividend.
How do I buy Vera Therapeutics shares?
To buy shares in Vera Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vera Therapeutics?
As of the previous close price of $23.22, shares in Vera Therapeutics had a market capitalisation of $1.48bn.
Where are Vera Therapeutics shares listed?
Here are the trading details for Vera Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VERA
What kind of share is Vera Therapeutics?
Based on an overall assessment of its quality, value and momentum Vera Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vera Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Vera Therapeutics is $65.23. That is 180.92% above the last closing price of $23.22.
Analysts covering Vera Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.15 for the next financial year.
Find out moreWhat is the trend in the Vera Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vera Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -40.44%.
As of the last closing price of $23.22, shares in Vera Therapeutics were trading -36.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vera Therapeutics PE Ratio?
The Vera Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $23.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vera Therapeutics?
Vera Therapeutics' management team is headed by:
- Kurt Von Emster - NEC
- Marshall Fordyce - CEO
- Sean Grant - CFO
- Tom Doan - SVP
- Joanne Curley - EXO
- Lauren Frenz - EXO
- Celia Lin - OTH
- Kimball Hall - DRC
- Andrew Cheng - IND
- Patrick Enright - IND
- Maha Katabi - IND
- Scott Morrison - IND
- Beth Seidenberg - IND